AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 7044532
Drug: Levamisole immunotherapy
RxNorm normalized name: Levamisole
DrugBank: Levamisole (DB00848)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Levamisole immunotherapy with radiation therapy
Trial: 7044532
Drug: Combined arms
RxNorm normalized name: ARM-210
DrugBank: ARM-210 (DB16944)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined arms with chemotherapy and/or immunotherapy
Trial: 31918243
Drug: Motor-phonetic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Motor-phonetic treatment
Trial: 31918243
Drug: Combined phonetic-phonological
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined phonetic-phonological treatment
Trial: 30477763
Drug: High-dose subcutaneous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose subcutaneous treprostinil (target dose around 30 ng/kg per min at week 12)
Trial: 30477763
Drug: Low-dose subcutaneous
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose subcutaneous treprostinil (target dose around 3 ng/kg per min at week 12)
Trial: 30477763
Drug: Comparison of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison of high-dose vs low-dose subcutaneous treprostinil
Trial: 26919407
Drug: Cavuplasty (creating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cavuplasty (creating a small cavity in the vertebral body prior to cement injection)
Trial: 27385833
Drug: Two consecutive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two consecutive real cervical spinal manipulative therapy (SMT) interventions to C5‐C6 segment
Trial: 21936966
Drug: Selenomethionine (SeMet)
RxNorm normalized name: selenomethionine
DrugBank: Selenomethionine (DB11142)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Selenomethionine (SeMet) supplementation at doses of 0, 50, 100, or 200 μg/d
Trial: 17600165
Drug: Cognitive-behavior treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavior treatment (CBT)
Trial: 8145914
Drug: 2.0 mg
RxNorm normalized name: LORAZEPAM 2.0 mg in 1 mL INTRAVENOUS INJECTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.0 mg Dihydroergotamine (DHE) nasal spray (0.5 mg per nostril, repeated after 15 minutes)
Trial: 3062540
Drug: Ketorolac tromethamine
RxNorm normalized name: Ketorolac Tromethamine
DrugBank: Ketorolac (DB00465)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ketorolac tromethamine solution 0.5% (1 drop 3 times daily)
Trial: 3062540
Drug: Placebo vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo vehicle solution
Trial: 3062540
Drug: Ketorolac tromethamine
RxNorm normalized name: Ketorolac Tromethamine
DrugBank: Ketorolac (DB00465)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ketorolac tromethamine solution 0.5%
Trial: 31407622
Drug: Pushen capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pushen capsule
Trial: 31407622
Drug: Pushen capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pushen capsule and Ginkgo biloba
Trial: 29148175
Drug: Probiotic cocktail
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic cocktail (Lactobacilli, Bifidobacteria, and Streptococcus thermophilus) once daily for 12 weeks
Trial: 25846824
Drug: Activities of
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Activities of daily living (ADL) score <12 of 15
Trial: 21894687
Drug: Eye acupuncture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eye acupuncture therapy
Trial: 21894687
Drug: Ibuprofen Sustained
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ibuprofen Sustained Release Capsules, 300 mg orally, 1-2 days before menses or when symptoms appeared, every 12 hours for 3-5 days
Trial: 16739330
Drug: High-dose neoadjuvant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose neoadjuvant treatment with cyclophosphamide and epirubicin
Trial: 11511713
Drug: Sildenafil citrate
RxNorm normalized name: Sildenafil Citrate
DrugBank: Sildenafil (DB00203)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sildenafil citrate (Viagra) 50 mg
Trial: 29269513
Drug: BMS‐986120 (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BMS‐986120 (60 mg)
Trial: 25939641
Drug: Oral sucrose
RxNorm normalized name: TootSweet 24% Oral Sucrose Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral sucrose + facilitated tucking
Trial: 25939641
Drug: Non-nutritive sucking
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-nutritive sucking + oral sucrose
Trial: 25939641
Drug: Non-nutritive sucking
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-nutritive sucking + oral sucrose + facilitated tucking
Trial: 19406976
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg phosphorus meal
Trial: 19406976
Drug: 1200 mg
RxNorm normalized name: aspirin 1200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1200 mg phosphorus meal
Trial: 11773672
Drug: Traditional Chinese
RxNorm normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional Chinese medicine (specific intervention not detailed)
Trial: 11773672
Drug: Conventional drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional drug development model (implied control)
Trial: 12145765
Drug: Fructose (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fructose (75 g)
Trial: 28549436
Drug: Cross-linked sodium
RxNorm normalized name: riboflavin 5'-phosphate
DrugBank: Flavin mononucleotide (DB03247)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cross-linked sodium hyaluronate (XLHA, single injection)
Trial: 28549436
Drug: High molecular
RxNorm normalized name: dextran, high molecular weight
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High molecular weight sodium hyaluronate (HMWHA, three injections)
Trial: 18555517
Drug: Infusion of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusion of activated autologous T cells
Trial: 17031403
Drug: Interleukin-2 (IL-2)
RxNorm normalized name: Fusion protein comprised of a circularly-permuted interleukin-2 (IL-2) with the extracellular domain of IL-2 receptor alpha
DrugBank: Human interleukin-2 (DB14865)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interleukin-2 (IL-2) group; received four doses of 10 x 10(6) IU m(‐2) twice daily subcutaneously a week before operation followed by a daily maintenance dose of 3 x 10(6) IU m(‐2) subcutaneously until a day before the operation.
Trial: 17031403
Drug: Interleukin-2 (IL-2)
RxNorm normalized name: Fusion protein comprised of a circularly-permuted interleukin-2 (IL-2) with the extracellular domain of IL-2 receptor alpha
DrugBank: Human interleukin-2 (DB14865)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interleukin-2 (IL-2) group; received IL-2 treatment.
Trial: 15334869
Drug: Oral glutamine
RxNorm normalized name: Glutamine
DrugBank: L-Glutamine (DB00130)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral glutamine (10 grams three times a day for 5 days)
Trial: 17168431
Drug: Oral glutamine
RxNorm normalized name: Glutamine
DrugBank: L-Glutamine (DB00130)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral glutamine
Trial: 10845968
Drug: Interventions to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interventions to change professional practice in primary care; specific details on dosage and duration not available.
Trial: 7710841
Drug: Transfusion treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transfusion treatment
Trial: 3236318
Drug: Amiloride 5
RxNorm normalized name: amiloride 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amiloride 5 mg once daily
Trial: 17885562
Drug: Nitrendipine 20
RxNorm normalized name: nitrendipine 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitrendipine 20 mg twice daily
Trial: 25526733
Drug: Everolimus (70
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Everolimus (70 mg/wk) with temozolomide and radiotherapy
Trial: 17156464
Drug: Acupuncture (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture (up to 10 treatments over 3 months)
Trial: 10933361
Drug: Omapatrilat (high
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omapatrilat (high dose)
Trial: 8299252
Drug: Intermittent high-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent high-dose pulse cyclophosphamide (Cy) and oral prednisone
Trial: 8299252
Drug: Daily oral
RxNorm normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily oral low-dose cyclophosphamide (Cy) and oral prednisone
Trial: 8299252
Drug: High-dose co-trimoxazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose co-trimoxazole therapy
Trial: 3032814
Drug: Intramuscular iodinated
RxNorm normalized name: Iodine
DrugBank: Iodine (DB05382)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intramuscular iodinated oil given before conception
Trial: 3032814
Drug: Intramuscular iodinated
RxNorm normalized name: Iodine
DrugBank: Iodine (DB05382)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intramuscular iodinated oil
Trial: 8853757
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg omeprazole daily for 9 days
Trial: 8853757
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg omeprazole daily for 9 days
Trial: 8853757
Drug: Long-term therapy
RxNorm normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Long-term therapy with omeprazole (mean duration 56 months) in GERD patients
Trial: 3883917
Drug: Etretinate (Tigason)
RxNorm normalized name: etretinate
DrugBank: Etretinate (DB00926)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Etretinate (Tigason) up to 0.5 mg/kg/day
Trial: 30153464
Drug: 13-min daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 13-min daily guided meditation session for 8 weeks
Trial: 30153464
Drug: 13-min daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 13-min daily podcast listening session (control group) for 8 weeks
Trial: 24270743
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of HFABP and troponin
Trial: 22095207
Drug: Standard rehabilitation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard rehabilitation plus NMES applied to the quadriceps muscle, initiated 48 hours after surgery, applied twice per day at maximum tolerable intensity for 15 contractions.
Trial: 18663117
Drug: Ultrasound (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasound (1 MHz, 0.5 W/cm(2)) once daily, six times a week for seven weeks (Groups 1 and 3)
Trial: 18663117
Drug: Surgical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical treatment (Groups 1 and 2)
Trial: 18663117
Drug: Conservative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conservative treatment with ultrasound (Group 3)
Trial: 16351668
Drug: EZE/SIMVA 10/20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EZE/SIMVA 10/20 mg/day
Trial: 16846545
Drug: ATV 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ATV 20 mg/day
Trial: 11915724
Drug: Surgery combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgery combined with chemo- and/or radiation therapies
Trial: 10342337
Drug: Humalog insulin
RxNorm normalized name: insulin lispro Cartridge [Humalog]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Humalog insulin
Trial: 16321271
Drug: Human soluble
RxNorm normalized name: Recombinant human soluble insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Human soluble insulin
Trial: 25027478
Drug: Cognitive Remediation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Remediation Therapy for 8 weeks followed by Cognitive Behavioral Therapy for 8 weeks
Trial: 29738810
Drug: Conventional cigarettes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional cigarettes (CC)
Trial: 19317065
Drug: Magnesium group
RxNorm normalized name: Magnesium
DrugBank: Magnesium (DB14513)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Magnesium group (MgSO4 30 mg/kg in saline)
Trial: 17410461
Drug: Omeprazole 10
RxNorm normalized name: omeprazole 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 10 mg once daily (od)
Trial: 17410461
Drug: Omeprazole 20
RxNorm normalized name: omeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 20 mg once daily (od)
Trial: 17410461
Drug: Omeprazole 40
RxNorm normalized name: omeprazole 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 40 mg once daily (od)
Trial: 17410461
Drug: Omeprazole 10
RxNorm normalized name: omeprazole 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 10 mg twice daily (bid)
Trial: 27289472
Drug: Omeprazole 20
RxNorm normalized name: omeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 20 mg twice daily (bid)
Trial: 15626258
Drug: Tetracaine/adrenaline solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tetracaine/adrenaline solution
Trial: 11223706
Drug: CC +
RxNorm normalized name: CC
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CC + ethinyl estradiol (0.05 mg)
Trial: 11223706
Drug: CC +
RxNorm normalized name: CC
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CC + ethinyl estradiol (0.02 mg)
Trial: 2811377
Drug: Vaginal oestriol
RxNorm normalized name: estriol Vaginal Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaginal oestriol (E3) therapy at a dose of 0.5 mg per day
Trial: 2811377
Drug: Vaginal oestradiol
RxNorm normalized name: estradiol Vaginal Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaginal oestradiol (E2) therapy at a dose of 0.05 mg per day
Trial: 2811377
Drug: Vaginal E3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaginal E3 therapy
Trial: 31438878
Drug: Magnesium sulfate
RxNorm normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Magnesium sulfate (MgSO4) infusion for 72 hours
Trial: 31438878
Drug: Placebo infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo infusion for 72 hours
Trial: 31438878
Drug: Magnesium sulfate
RxNorm normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Magnesium sulfate (MgSO4) as second line therapy in observational cohort
Trial: 28438473
Drug: Chemotherapy plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy plus bevacizumab (15 mg/kg every 3 weeks)
Trial: 28438473
Drug: Standard chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard chemotherapy (paclitaxel 175 mg/m2 and carboplatin AUC 5)
Trial: 19377755
Drug: Cimetidine 35
RxNorm normalized name: cimetidine 350 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine 35 mg/Kg/day (maximum 1200 mg/day) for three months
Trial: 19377755
Drug: Zinc sulphate
RxNorm normalized name: Zinc sulphate
DrugBank: Zinc acetate (DB14487)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Zinc sulphate 10 mg/Kg/day (maximum 600 mg/day) for three months
Trial: 17617271
Drug: TMC125 (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TMC125 (200 mg) twice daily with darunavir-ritonavir and other antiretrovirals
Trial: 11256874
Drug: Conjugated estrogen
RxNorm normalized name: Conjugated estrogen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conjugated estrogen (0.625 mg/d, Premarin) and medroxyprogesterone acetate (5 mg/d, Farlutal)
Trial: 11907941
Drug: Continuous progestin
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous progestin regimen in combination with estrogen
Trial: 8041979
Drug: Clonidine (0.005
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clonidine (0.005 mg/kg/po)
Trial: 8041979
Drug: Lorazepam (0.03
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lorazepam (0.03 mg/kg/po)
Trial: 31758835
Drug: Topical latanoprost
RxNorm normalized name: Latanoprost
DrugBank: Latanoprost (DB00654)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Topical latanoprost gel twice daily for 12 weeks
Trial: 19924010
Drug: CHO (6%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CHO (6% carbohydrate supplement)
Trial: 19924010
Drug: CHO/PRO L
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CHO/PRO L (3% carbohydrate plus 0.75% protein complex)
Trial: 19924010
Drug: CHO, CHO/PRO
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CHO, CHO/PRO H, CHO/PRO L
Trial: 1715450
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of hydrochlorothiazide and triamterene
Trial: 1826071
Drug: Diuretics alone
RxNorm normalized name: hydralazine hydrochloride / hydrochlorothiazide / reserpine Oral Tablet [Diuretic Ap-Es]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diuretics alone or diuretics plus methyldopa
Trial: 7333741
Drug: Trial A
RxNorm normalized name: Trial Antacid
DrugBank: Calcium carbonate (DB06724)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Trial A (3 days L, 3 days H)
Trial: 25751329
Drug: Half-dose group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Half-dose group (methotrexate 0.15 mg/kg weekly)
Trial: 25751329
Drug: 2-weekly group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2-weekly group (methotrexate 0.3 mg/kg every 2 weeks)
Trial: 24176390
Drug: Inhaled aztreonam
RxNorm normalized name: aztreonam Inhalation Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled aztreonam (AZLI)
Trial: 22902212
Drug: Bevacizumab (intraocular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bevacizumab (intraocular injections every 6 weeks for 12 months)
Trial: 22902212
Drug: Sham injections
RxNorm normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham injections (first 6 months), then Bevacizumab (intraocular injections every 6 weeks for 6 months)
Trial: 17882731
Drug: Mebeverine hydrochloride
RxNorm normalized name: Mebeverine hydrochloride
DrugBank: Mebeverine (DB12554)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mebeverine hydrochloride film-forming gel
Trial: 15333608
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of physical exercise and high altitude (Protocol III)
Trial: 9475762
Drug: Finasteride (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Finasteride (5 mg daily for four years)
Trial: 8553300
Drug: Twice daily
RxNorm normalized name: CAPSULE, TWICE DAILY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice daily inhaled budesonide (400 micrograms morning and bedtime)
Trial: 8553300
Drug: Once daily
RxNorm normalized name: GEL, ONCE DAILY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily inhaled budesonide (800 micrograms at bedtime)
Trial: 436626
Drug: 1.0 mg
RxNorm normalized name: HYDROCORTISONE BUTYRATE 1.0 mg in 1 g TOPICAL CREAM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 mg digoxin by mouth
Trial: 436626
Drug: 1.0 mg
RxNorm normalized name: HYDROCORTISONE BUTYRATE 1.0 mg in 1 g TOPICAL CREAM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 mg beta-acetyldigoxin by mouth
Trial: 436626
Drug: Orally administered
RxNorm normalized name: no vaccine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orally administered digoxin
Trial: 436626
Drug: Orally administered
RxNorm normalized name: no vaccine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orally administered beta-acetyldigoxin
Trial: 436626
Drug: Intravenously administered
RxNorm normalized name: no vaccine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenously administered digoxin
Trial: 29976285
Drug: Rivaroxaban 2.5
RxNorm normalized name: rivaroxaban 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rivaroxaban 2.5 mg orally twice per day
Trial: 22290521
Drug: Customized Power
RxNorm normalized name: guaifenesin
DrugBank: Guaifenesin (DB00874)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Customized Power Balance performance mouth guard (PB MG)
Trial: 22290521
Drug: Regular over
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular over the counter boil-and-bite mouth guard (Reg MG)
Trial: 22290521
Drug: No mouth
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No mouth guard (No MG)
Trial: 15030966
Drug: Standard amino
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard amino acid solution (n = 10)
Trial: 15030966
Drug: Branched chain
RxNorm normalized name: Branched Chain Amino Acids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Branched chain amino acid enriched solution (n = 10)
Trial: 11474314
Drug: Amtolmetin‐guacyl (AMG)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amtolmetin‐guacyl (AMG) 1200 mg for 2 days and 600 mg for 12 days
Trial: 11474314
Drug: Piroxicam 40
RxNorm normalized name: piroxicam 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piroxicam 40 mg for 2 days and 20 mg for 12 days
Trial: 30993452
Drug: FACT-G Physical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FACT-G Physical Wellbeing
Trial: 30993452
Drug: FACT-G Total
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FACT-G Total